Wang and colleagues reported that high TMB estimated by the blood levels of ctDNA indicated better PFS and was associated with higher objective response rates than low blood TMB in patients with non-small cell lung cancer who received anti-PD1 and anti-PD-L1 therapy14. The gene discussed is CD274; the disease is non-small cell lung carcinoma.